Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Interest & Investment Income (2023 - 2025)

Denali Therapeutics (DNLI) has disclosed Interest & Investment Income for 3 consecutive years, with $8.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 41.18% to $8.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $42.9 million, a 33.62% decrease, with the full-year FY2025 number at $42.9 million, down 33.62% from a year prior.
  • Interest & Investment Income was $8.9 million for Q4 2025 at Denali Therapeutics, down from $10.5 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $17.6 million in Q2 2024 to a low of $8.9 million in Q4 2025.
  • A 3-year average of $13.3 million and a median of $13.5 million in 2023 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: surged 44.22% in 2024, then tumbled 41.18% in 2025.
  • Denali Therapeutics' Interest & Investment Income stood at $14.4 million in 2023, then grew by 4.98% to $15.2 million in 2024, then crashed by 41.18% to $8.9 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Interest & Investment Income are $8.9 million (Q4 2025), $10.5 million (Q3 2025), and $10.8 million (Q2 2025).